Trials Today

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Atopic Dermatitis

The purpose of this study is to assess the efficacy and safety of RO7790121 in participants with moderate to severe atopic dermatitis (AD).

AD diagnosis confirmed by a dermatologist according to the Hanifin/Rajka criteria at least 1 year prior to screening - Moderate to severe AD - At least once daily use of an additive-free, bland emollient for at least 7 days prior to the baseline visit and during the study

Evidence of other skin conditions that would interfere with the assessment of AD, including, but not limited to, for example cutaneous T-cell lymphoma, allergic contact dermatitis - IV, IM, IL, and oral corticosteroids (inhaled, ophthalmic drops, and nasal corticosteroids are allowed) within 4 weeks of the baseline visit and during the study - Topical treatment for AD including, but not limited to topical corticosteroids, topical calcineurin Inhibitors, topical PDE-4 inhibitors, , prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea or filaggrin within 7 days prior to the baseline visit and during the study - Any active infection or other active skin diseases that required treatment with parenteral anti-infectives within 4 weeks or oral anti-infective treatment within 2 weeks prior to baseline - Acquired or congenital immunodeficiency - Systemic therapies that are also used in the treatment of AD, including, but not limited to methotrexate, cyclosporine, azathioprine, mycophenolate mofetil within 4 weeks of the baseline visit and during the study

Arm	Description	Assigned Intervention
Experimental RO7790121 Group I	Participants will receive RO7790121 via subcutaneous (SC) injection.	Drug: RO7790121 RO7790121 will be administered as SC injection. Other names: PF-06480605 RVT-3101
Experimental RO7790121 Group II	Participants will receive RO7790121 via SC injection.	Drug: RO7790121 RO7790121 will be administered as SC injection. Other names: PF-06480605 RVT-3101
Experimental RO7790121 Group III	Participants will receive RO7790121 via SC injection.	Drug: RO7790121 RO7790121 will be administered as SC injection. Other names: PF-06480605 RVT-3101
Placebo Comparator Placebo	Participants will receive placebo via SC injection.	Drug: Placebo Placebo will be administered as SC injection.

Dermatology Research Associate
Los Angeles, California 90045

Suncoast Research Associates LLC - ERN - PPDS
Miami, Florida 33173

Hamilton Research, LLC
Alpharetta, Georgia 30022

Dermatology Affiliates Research Institute, LLC
Atlanta, Georgia 30305

Dawes Fretzin Clinical Res LLC
Indianapolis, Indiana 46250

Revival Research Institute, LLC
Troy, Michigan 48084

Care Access Research - Hoboken
Hoboken, New Jersey 07030

Best Skin Research LLC
Camp Hill, Pennsylvania 17011

Goodlettsville Dermatology Research
Goodlettsville, Tennessee 37072

Cumberland Skin Center for Clinical Research LLC
Hermitage, Tennessee 37076

Arlington Research Center
Arlington, Texas 76011

Modern Research Associates
Dallas, Texas 75231

Reveal Research Institute
Dallas, Texas 75235

Reference Study ID Number: CS45570 https://forpatients.roche.com/
888-662-6728 (U.S. and Canada)
global-roche-genentech-trials@gene.com